Form 4: Avidity Biosciences Chief Commercial Officer Acquires Stock and Options

Avidity Biosciences' Chief Commercial Officer, Eric Mosbrooker, acquired 25,000 shares of restricted stock units and options for 50,000 shares on January 6, 2025.

Summary

• Eric Mosbrooker, Chief Commercial Officer of Avidity Biosciences, acquired 25,000 restricted stock units (RSUs) and options for 50,000 shares of common stock on January 6, 2025.
• The RSUs vest in four equal installments on the first four anniversaries of January 6, 2025, contingent on continuous service.
• The stock options vest in 48 equal monthly installments from the grant date, fully vesting on January 6, 2029.
• The exercise price of the stock options is $31.42.
• Following these transactions, Mr. Mosbrooker directly owns 61,120 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine insider transaction, which is generally positive as it shows management's confidence in the company. However, it is not a major event that would significantly impact the company's valuation.

Positives

• The acquisition of stock and options by a key executive like the Chief Commercial Officer can be seen as a positive sign of confidence in the company's future prospects.
• The vesting schedules for both the RSUs and options align the executive's interests with the long-term performance of the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with shareholder value.
• The vesting schedules described are typical for such grants, with vesting periods ranging from 3 to 5 years.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the executive's interests with the company's performance.

Key Dates

Keywords

Avidity Biosciences, RNA, insider trading, stock options, restricted stock units, executive compensation, SEC Form 4, Eric Mosbrooker, Chief Commercial Officer